JO3476B1 - بروتينات مندمجة لعلاج الاضطرابات الايضية - Google Patents

بروتينات مندمجة لعلاج الاضطرابات الايضية

Info

Publication number
JO3476B1
JO3476B1 JOP/2012/0279A JOP20120279A JO3476B1 JO 3476 B1 JO3476 B1 JO 3476B1 JO P20120279 A JOP20120279 A JO P20120279A JO 3476 B1 JO3476 B1 JO 3476B1
Authority
JO
Jordan
Prior art keywords
fusion proteins
metabolic disorders
treating metabolic
fgf21
treating
Prior art date
Application number
JOP/2012/0279A
Other languages
English (en)
Inventor
Licht Stuart
R Boettcher Brian
Hamamatsu Norio
S Daniels Douglas
Craig Weldon Stephen
L Caplan Shari
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3476B1 publication Critical patent/JO3476B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلق الاختراع بتعريف بروتين دمج يشتمل على عديد ببتيد<br /> جديد و متغيرات بروتين من عامل نمو الخلايا الليفية 21<br /> ( FGF21 ( التي لها خصائص صيدلية محسنة. و يفصح<br /> أيض ا عن طرق لعلاج الأمراض المرتبطة ب FGF21<br /> متضمنة الحالات الايضية
JOP/2012/0279A 2011-09-26 2012-09-25 بروتينات مندمجة لعلاج الاضطرابات الايضية JO3476B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161539280P 2011-09-26 2011-09-26

Publications (1)

Publication Number Publication Date
JO3476B1 true JO3476B1 (ar) 2020-07-05

Family

ID=46970456

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0279A JO3476B1 (ar) 2011-09-26 2012-09-25 بروتينات مندمجة لعلاج الاضطرابات الايضية

Country Status (41)

Country Link
US (6) US9006400B2 (ar)
EP (2) EP2760475B1 (ar)
JP (4) JP6186361B2 (ar)
KR (1) KR102085605B1 (ar)
CN (2) CN107266579B (ar)
AP (1) AP2014007543A0 (ar)
AR (2) AR088044A1 (ar)
AU (1) AU2012316052A1 (ar)
BR (1) BR112014007069B1 (ar)
CA (1) CA2849464C (ar)
CL (2) CL2014000736A1 (ar)
CO (1) CO6920257A2 (ar)
CR (1) CR20140140A (ar)
CU (2) CU24314B1 (ar)
CY (2) CY1120928T1 (ar)
DK (2) DK3321276T3 (ar)
EA (1) EA039633B1 (ar)
ES (2) ES2689762T3 (ar)
GT (1) GT201400055A (ar)
HR (2) HRP20181558T1 (ar)
HU (2) HUE039857T2 (ar)
IL (1) IL231533B (ar)
IN (1) IN2014DN02043A (ar)
JO (1) JO3476B1 (ar)
LT (2) LT3321276T (ar)
MA (1) MA35437B1 (ar)
MX (1) MX350273B (ar)
MY (1) MY166059A (ar)
PE (2) PE20141551A1 (ar)
PL (2) PL2760475T3 (ar)
PT (2) PT3321276T (ar)
RS (2) RS62341B1 (ar)
SG (2) SG10201602339XA (ar)
SI (2) SI2760475T1 (ar)
SM (1) SMT202100595T1 (ar)
TN (1) TN2014000109A1 (ar)
TW (1) TWI593708B (ar)
UA (1) UA113856C2 (ar)
UY (2) UY34346A (ar)
WO (1) WO2013049247A1 (ar)
ZA (1) ZA201401700B (ar)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544680A (ja) 2006-07-25 2009-12-17 リポクセン テクノロジーズ リミテッド ポリサッカライドによるタンパク質のｎ末端誘導体化
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
ES2748038T3 (es) 2011-07-01 2020-03-12 Ngm Biopharmaceuticals Inc Composiciones, usos y métodos para el tratamiento de trastornos y enfermedades metabólicos
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
SI2791160T1 (sl) 2011-12-16 2022-07-29 Modernatx, Inc. Sestave modificirane MRNA
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
EP2925775B1 (en) 2012-11-28 2020-09-16 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP2938740B1 (en) 2012-12-27 2022-04-20 NGM Biopharmaceuticals, Inc. Chimeric fgf19 peptides for use in treating bile acid disorders
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3057605A1 (en) 2013-10-18 2016-08-24 Novartis AG Methods of treating diabetes and related disorders
KR102178945B1 (ko) 2013-10-28 2020-11-13 엔지엠 바이오파마슈티컬스, 아이엔씨. 암 모델 및 관련 방법
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL251834B2 (en) * 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc Pharmaceutical compositions containing peptide variants and methods of using them
SG11201702824UA (en) 2014-10-24 2017-05-30 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
EP3331914A1 (en) * 2015-08-03 2018-06-13 Novartis AG Methods of treating fgf21-associated disorders
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
ES2871036T3 (es) 2015-11-09 2021-10-28 Ngm Biopharmaceuticals Inc Método para el tratamiento de trastornos relacionados con ácidos biliares
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
BR112018073861A2 (pt) * 2016-05-20 2019-02-26 President And Fellows Of Harvard College métodos de terapia de genes para doenças e condições relacionadas com a idade
CA3026510A1 (en) * 2016-05-25 2017-11-30 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of secretory disorders
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CA3047862A1 (en) 2016-12-22 2018-06-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
JP7181886B2 (ja) * 2017-03-14 2022-12-01 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質
CN107050429B (zh) * 2017-04-01 2020-12-15 杭州生物医药创新研究中心 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用
EP3619324B1 (en) 2017-05-05 2025-07-09 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN109836504B (zh) * 2017-11-24 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
WO2019119673A1 (zh) 2017-12-19 2019-06-27 北京吉源生物科技有限公司 一种双基因修饰的干细胞及其用途
CN119386162A (zh) * 2017-12-22 2025-02-07 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
CN110128525B (zh) 2018-02-08 2022-08-26 广东东阳光药业有限公司 Fgf21变体、融合蛋白及其应用
JP2021528422A (ja) * 2018-06-21 2021-10-21 サノフイＳａｎｏｆｉ 最適化された活性比を有するｆｇｆ２１化合物／ｇｌｐ−１ｒアゴニストの組合せ
CN112601517A (zh) 2018-07-03 2021-04-02 百时美施贵宝公司 Fgf-21配制品
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
CN114853908B (zh) 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
CN112386575B (zh) * 2019-08-19 2023-03-21 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干制剂
EP4028413A1 (en) 2019-09-10 2022-07-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
KR20220119424A (ko) 2019-12-20 2022-08-29 노파르티스 아게 인테그린 억제제를 사용한 간 질환의 조합 치료
JP6924291B2 (ja) 2020-01-21 2021-08-25 シャープ株式会社 端末装置、方法、および、集積回路
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
KR20230034357A (ko) * 2020-07-02 2023-03-09 사노피 Glp-1r 작용제/fgf21 융합 단백질
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
CN113265007B (zh) * 2021-06-10 2022-02-15 江南大学 一种治疗代谢疾病的融合蛋白及其制备方法和应用
CN115286705B (zh) * 2021-12-30 2024-05-10 长江大学 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用
WO2023245543A1 (en) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Uses of fgf21 fusion proteins
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2025108432A1 (en) * 2023-11-23 2025-05-30 Therorna Shanghai Co., Ltd. Circular rna encoding fgf21 and the use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
EP0315456B1 (en) 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
ES2335386T3 (es) 1999-11-18 2010-03-26 Novartis Vaccines And Diagnostics, Inc. Gen fgf-21 humano y productos de expresion genica.
DE60043957D1 (de) 1999-12-23 2010-04-15 Zymogenetics Inc Verfahren zur Behandlung von Entzündungen
AU2002322394A1 (en) 2001-07-30 2003-02-17 Eli Lilly And Company Method for treating diabetes and obesity
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
WO2005061712A1 (en) * 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
PT1751184E (pt) * 2004-05-13 2009-11-10 Lilly Co Eli Proteínas de fusão de fgf-21
SI1789442T1 (sl) * 2004-09-02 2010-01-29 Lilly Co Eli Proteinske mutante fibroblastnega rastnega faktorja 21
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EA021001B1 (ru) 2008-10-24 2015-03-31 Новартис Аг Биосинтетический пирролинкарбоксилизин и сайт-специфичные модификации белка за счет химической модификации остатков пирролинкарбоксилизина и пирролизина
US20120052069A1 (en) * 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
SG10201402038WA (en) * 2009-05-05 2014-07-30 Amgen Inc FGF21 Mutants And Uses Thereof
AU2010262927A1 (en) * 2009-06-17 2012-01-19 Amgen Inc. Chimeric FGF19 polypeptides and uses thereof
CA2785139A1 (en) 2009-12-22 2011-06-30 Novartis Ag Tetravalent cd47-antibody constant region fusion protein for use in therapy
DE102010038140B4 (de) * 2010-10-13 2020-06-18 Hettich-Heinze Gmbh & Co. Kg Beschlag für eine Schiebetür
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
TWI593708B (zh) * 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling

Also Published As

Publication number Publication date
EA201490695A1 (ru) 2015-10-30
EP2760475B1 (en) 2018-07-04
LT2760475T (lt) 2018-10-25
WO2013049247A1 (en) 2013-04-04
CA2849464C (en) 2024-01-30
AR088044A1 (es) 2014-05-07
SI3321276T1 (sl) 2021-11-30
SG10201602339XA (en) 2016-05-30
US20180369332A1 (en) 2018-12-27
CU24314B1 (es) 2018-02-08
ES2689762T3 (es) 2018-11-15
SG11201400538QA (en) 2014-06-27
JP2014534172A (ja) 2014-12-18
UY39119A (es) 2021-04-30
CU24206B1 (es) 2016-10-28
HUE039857T2 (hu) 2019-02-28
US20240261372A1 (en) 2024-08-08
TWI593708B (zh) 2017-08-01
HK1251238A1 (en) 2019-01-25
US20130079500A1 (en) 2013-03-28
UY34346A (es) 2013-04-30
HRP20181558T1 (hr) 2018-11-30
NZ622998A (en) 2016-07-29
TW201326213A (zh) 2013-07-01
EA039633B1 (ru) 2022-02-18
JP2020007314A (ja) 2020-01-16
CR20140140A (es) 2014-07-15
CA2849464A1 (en) 2013-04-04
US10076554B2 (en) 2018-09-18
DK2760475T3 (en) 2018-10-15
JP2018023370A (ja) 2018-02-15
CN103945871A (zh) 2014-07-23
MX350273B (es) 2017-08-31
US20150166622A1 (en) 2015-06-18
PL2760475T3 (pl) 2018-11-30
US20160193297A1 (en) 2016-07-07
AR123908A2 (es) 2023-01-25
HUE055584T2 (hu) 2021-12-28
CY1120928T1 (el) 2019-12-11
PT3321276T (pt) 2021-10-27
PT2760475T (pt) 2018-10-25
SMT202100595T1 (it) 2022-01-10
PL3321276T3 (pl) 2022-01-17
UA113856C2 (xx) 2017-03-27
PE20181159A1 (es) 2018-07-19
PE20141551A1 (es) 2014-10-26
IN2014DN02043A (ar) 2015-05-15
CO6920257A2 (es) 2014-04-10
MA35437B1 (fr) 2014-09-01
JP6567613B2 (ja) 2019-08-28
MX2014003677A (es) 2014-04-30
LT3321276T (lt) 2021-11-10
SI2760475T1 (sl) 2018-10-30
US9006400B2 (en) 2015-04-14
CN107266579A (zh) 2017-10-20
GT201400055A (es) 2017-09-28
BR112014007069B1 (pt) 2020-12-15
TN2014000109A1 (en) 2015-07-01
AU2012316052A1 (en) 2014-04-17
MY166059A (en) 2018-05-22
EP3321276A2 (en) 2018-05-16
HRP20211575T1 (hr) 2022-02-04
CN107266579B (zh) 2022-07-12
CU20150171A7 (es) 2016-07-29
ZA201401700B (en) 2015-01-28
AP2014007543A0 (en) 2014-03-31
EP3321276B1 (en) 2021-07-28
JP6186361B2 (ja) 2017-08-23
EP2760475A1 (en) 2014-08-06
DK3321276T3 (da) 2021-10-25
KR20140069250A (ko) 2014-06-09
CN103945871B (zh) 2017-04-26
ES2895080T3 (es) 2022-02-17
US11129874B2 (en) 2021-09-28
US9266935B2 (en) 2016-02-23
IL231533B (en) 2018-06-28
JP7339372B2 (ja) 2023-09-05
US11944664B2 (en) 2024-04-02
IL231533A0 (en) 2014-04-30
EP3321276A3 (en) 2018-06-20
BR112014007069A2 (pt) 2017-03-28
US20210386824A1 (en) 2021-12-16
RS57868B1 (sr) 2018-12-31
JP2022058546A (ja) 2022-04-12
RS62341B1 (sr) 2021-10-29
CY1124697T1 (el) 2022-07-22
CL2014000736A1 (es) 2014-10-03
CL2016002215A1 (es) 2016-10-28
CU20140034A7 (es) 2014-08-28
KR102085605B1 (ko) 2020-03-06

Similar Documents

Publication Publication Date Title
TN2014000109A1 (en) Fusion proteins for treating metabolic disorders
PH12013501010A1 (en) Methods of treating fgf21-associated disorders
TN2014000110A1 (en) Dual function proteins for treating metabolic disorders
PH12014502766A1 (en) Fibroblast growth factor 21 proteins
MY163674A (en) Compositions, uses and method for treatment of metabolic disorders and diseases
MX2021006856A (es) Uso de un peptido para modular la homeostasis de los acidos biliares o tratamiento de una enfermedad relacionada con los acidos biliares.
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
WO2014085365A3 (en) Compositions and methods for treatment of metabolic disorders and diseases
TN2013000211A1 (en) Methods of treating fgf 21- associated disorders
GB201104285D0 (en) Modified receptor fusion proteins
TH145764A (th) วิธีการสำหรับการบำบัดความผิดปกติที่เกี่ยวข้องกับ fgf21